http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Blow-up of solutions for semilinear heat equation with nonlinear nonlocal boundary condition
Gladkov, A.,Kim, K.I. Academic Press 2008 Journal of mathematical analysis and applications Vol.338 No.1
In this paper, we consider a semilinear heat equation u<SUB>t</SUB>=Δu+c(x,t)u<SUP>p</SUP> for (x,t)@?Ωx(0,∼) with nonlinear and nonlocal boundary condition u|<SUB>@</SUB>?<SUB>&</SUB>Omega;<SUB>x(0,∼</SUB>;<SUB>)</SUB>=∫<SUB>&</SUB>Omega;k(x,y,t)u<SUP>l</SUP>dy and nonnegative initial data where p>0 and l>0. We prove global existence theorem for max(p,l)=<1. Some criteria on this problem which determine whether the solutions blow up in a finite time for sufficiently large or for all nontrivial initial data or the solutions exist for all time with sufficiently small or with any initial data are also given.
김우영,A. Gladkov,V. Kavtanyuk,선용근,C. C. Yun,J. W. Kim 한국물리학회 2015 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.66 No.3
Polarized rare isotope (RI) beams have been designed at the Rare Isotope Science Project (RISP)for the study of the nuclear-structure, nuclear-reaction and astrophysics experiments. A powerfulmethod has been adopted for this work − the production of polarized RI beams via projectilefragmentation. The in-flight system line was designed for this purpose at the RISP by using theprojectile fragmentation method. The working principle, schematic design and experiments to beperformed at the RISP will be presented.
LaBonte, Melissa J.,Yang, Dongyun,Zhang, Wu,Wilson, Peter M.,Nagarwala, Yasir M.,Koch, Kevin M.,Briner, Colleen,Kaneko, Tomomi,Rha, Sun-Young,Gladkov, Oleg,Urba, Susan G.,Sakaeva, Dina,Pishvaian, Mich American Association for Cancer Research 2016 Molecular Cancer Therapeutics Vol.15 No.9
<P>An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to determine the association of lapatinib-induced fluoropyrimidine gene changes with efficacy of lapatinib plus capecitabine as first-line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma-independent of tumor HER2 status. Tumor biopsies obtained before and after 7- day lapatinib (1,250 mg) to analyze changes in gene expression, followed by a 14-day course of capecitabine (1,000 mg/m(2) twice daily, 14/21 days) plus lapatinib 1,250 mg daily. Blood samples were acquired for pharmacokinetic analysis. Primary clinical objectives were response rate (RR) and 5-month progression-free survival (PFS). Secondary objectives were overall survival (OS), PFS, time to response, duration of response, toxicity, and identification of associations between lapatinib pharmacokinetics and biomarker endpoints. Primary biomarker objectives were modulation of 5FU- pathway genes by lapatinib, effects of germline SNPs on treatment outcome, and trough steady-state plasma lapatinib concentrations. Sixty-eight patients were enrolled; (75% gastric cancer, 25% gastroesophageal junction). Twelve patients (17.9%) had confirmed partial response, 31 (46.3%) had stable disease, and 16 (23.9%) had progressive disease. Median PFS and OS were 3.3 and 6.3 months, respectively. Frequent adverse events included diarrhea (45%), decreased appetite (39%), nausea (36%), and fatigue (36%). Lapatinib induced no changes in gene expression from baseline and no significant associations were found for SNPs analyzed. Elevated baseline HER3 mRNA expression was associated with a higher RR (33% vs. 0%; P = 0.008). Lapatinib plus capecitabine was well tolerated, demonstrating modest antitumor activity in patients with advanced gastric cancer. The association of elevated HER3 and RR warrants further investigation as an important player for HER-targeted regimens in combination with capecitabine. (C)2016 AACR.</P>